Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if the Bright Bodies (BB) Healthy Lifestyle Program can help reverse early abnormalities in glucose metabolism and prevent the progression to type 2 diabetes (T2DM) in high-risk, obese youth with newly-diagnosed impaired glucose tolerance (IGT).
| Condition | Intervention |
|---|---|
|
Impaired Glucose Tolerance |
Behavioral: Bright Bodies Healthy Lifestyle Program Behavioral: Control |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program |
- 2-hour plasma glucose, category of glucose tolerance (IGT, NGT, T2DM) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Homeostasis model assessment of insulin resistance (HOMA-IR) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Lipid profile [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Alanine aminotransferase (ALT) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Body mass index (BMI) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Body fat mass and % [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Blood pressure (BP) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Piers-Harris Self-concept scale score [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Child behavior checklist score [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Family assessment device (FAD) score [ Time Frame: 6 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 72 |
| Study Start Date: | September 2009 |
| Estimated Study Completion Date: | September 2011 |
| Estimated Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Family-based Healthy Lifestyle Program
Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
|
Behavioral: Bright Bodies Healthy Lifestyle Program
Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
|
| Active Comparator: Standard Diet & Activity Education (Control) |
Behavioral: Control
Subjects will be given basic instruction by clinical provider and goals will be followed up every 3 months.
|
Detailed Description:
Primary Aim: (1) To determine whether youth randomized to the Bright Bodies (BB) Healthy Lifestyle Program have lower 2-hr plasma glucose levels than those randomized to standard lifestyle counseling (control) after 6 months.
Secondary Aims: (2) To determine if greater conversions from IGT to normal glucose tolerance (NGT) and less development of T2DM occurs for those in the BB vs Control Group; (3)To determine if there is improvement in anthropometric/metabolic parameters in BB vs Control Group; and (4) To determine if there is an improvement in psychosocial and family dynamic outcomes of the child in BB vs Control Group.
Eligibility| Ages Eligible for Study: | 11 Years to 16 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of IGT (glucose 140-199 at 2 hrs during OGTT)
- Age 11 to 16
- An interest in being enrolled in a healthy lifestyle program
- A parent/caregiver willing to participate with child in program
Exclusion Criteria:
- Psychiatric disorder or serious medical condition that would preclude participation in program
- Currently taking medication that potentially effects insulin sensitivity (eg Metformin) or causes weight gain (example: Risperidone) or weight loss (eg Xenical)
- Involvement in co-existing weight management/healthy lifestyle program
- Plans of moving out of the Greater New Haven area within six months
Contacts and Locations| Contact: Mary Savoye, RD | 203-737-4384 | mary.savoye@yale.edu |
| United States, Connecticut | |
| Yale Center for Clinical Investigation | Recruiting |
| New Haven, Connecticut, United States, 06520 | |
| Contact: Mary Savoye, RD 203-737-4384 mary.savoye@yale.edu | |
| Principal Investigator: | Robert S. Sherwin, MD | Yale University |
More Information
No publications provided
| Responsible Party: | Robert Sherwin, MD, Principal Investigator, Yale University |
| ClinicalTrials.gov Identifier: | NCT01030978 History of Changes |
| Other Study ID Numbers: | 0908005608, 3UL1RR024139-04S2 |
| Study First Received: | December 10, 2009 |
| Last Updated: | December 11, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Yale University:
|
Impaired Glucose Tolerance PreDiabetes Diabetes Prevention |
Additional relevant MeSH terms:
|
Diabetes Mellitus, Type 2 Glucose Intolerance Diabetes Mellitus Glucose Metabolism Disorders |
Metabolic Diseases Endocrine System Diseases Hyperglycemia |
ClinicalTrials.gov processed this record on May 22, 2013